- References (2)
- Inventor Info
|Antigen/Gene or Protein Targets||MRCKβ|
|Parental Line||MDA-MB-231 D3H2LN-Luc cell line|
|Synonyms||Serine/threonine-protein kinase MRCK beta, CDC42-binding protein kinase beta, CDC42BP-beta, DMPK-like beta, Myotonic dystrophy kinase-related CDC42-binding kinase beta, MRCK beta, Myotonic dystrophy protein kinase-like beta|
|Disease Keywords||Triple negative breast cancer (TNBC)|
This cell line has been engineered to enable tetracycline inducible expression of the kinase MRCKβ. MRCKβ is a myotonic dystrophy kinase-related CDC42-binding kinase involved in regulating actin-myosin contractility and implicated in cancer metastasis. MRCKβ, in conjunction with MRCKα, ROCK1 and ROCK2 kinases, initiates signalling events that lead to contractile force generation which powers cancer cell motility and invasion.
The cell line is a derivative of a human breast cancer cell line shown to reliably metastasize to clinically relevant sites (the lungs and lymph nodes) when implanted orthotopically in mice (i.e. when implanted in the breast pad of mice). The cell line expresses luciferase enabling detection of the location of the cells using bioluminescent imaging. Useful for the study of breast cancer cell cytoskeleton reorganisation and cell migration. This cell line is derived from a triple negative breast cancer (TNBC) meaning it does not express oestrogen, progesterone or HER2 receptors.
|Conditional Description||MDA-MB-231 D3H2LN-Luc cell line that expresses tetracycline (Tet)-regulated transactivator Tet-On 3G regulated expression of MRCKβ. Therefore MRCKβ expression is induced in the presence of doxycycline.|
|Research Area||Cancer, Cell Structure and Motility, Drug Discovery & Development, Genetic Studies Tools|
|Growth/Phenotype Keywords||Adherent cell line. Membrane blebbing/cytoskeleton reorganisation and migration induced in the presence of doxycycline.|
|Recommended Growing Conditions||10% FBS/MEM-EBSS/NEAA/NaPyr/Glutamine|
Treatment with doxycycline induced MRCKβ kinase domain expression and resulted in increased MLC phosphorylation. Clone demonstrated profound membrane blebbing following doxycycline treatment. Transgene expression did not appear to be 'leaky' in any clones tested.
Tet-On System owned by TET Systems GmbH & Co. KG.
There are 2 reference entries for this reagent.View All References